MAB Discovery has entered into a second collaboration agreement with European biopharmaceutical company, BioNTech, which will see MAB Discovery’s technology platform applied to proprietary targets provided by BioNTech.
Collaboration
“We are excited to be selected again as a partner for BioNTech. This underscores the high performance of our rabbit-based antibody discovery platform,” said Dr Stephan Fischer, CEO of MAB Discovery.
Sean Marett, COO of BioNTech added: “Our collaboration with MAB Discovery in 2013 was highly productive and we are delighted to expand our relationship to generate unique antibodies against a set of therapeutically relevant targets.”
Financial terms of the agreement were not disclosed.